Skip to main content
. 2013 Jun;29(6):859–870. doi: 10.1089/aid.2012.0292

Table 3.

Summary Statistics for Raltegravir Sparse Pharmacokinetic Parameters by Gender and Race

PK parameter N LS mean (95% CI)a %CVb Median Min Max
Female
 GM all (nM) 91 338 (273, 419) 147 330 14 7,039
 GM C12 (nM) 60 331 (251, 437) 137 311 57 6,394
Cmin (nM) 91 99 (76, 128) 196 96 6 4,566
Male
 GM all (nM) 105 381 (312, 466) 134 344 5 5,800
 GM C12 (nM) 58 282 (212, 374) 165 274 7 15,291
 Cmin (nM) 105 83 (65, 105) 197 80 5 5,800
Black
 GM all (nM) 146 353 (298, 418) 121 302 29 5,800
 GM C12 (nM) 90 285 (227, 357) 139 274 7 6,394
Cmin (nM) 146 93 (76, 115) 189 89 6 5,800
Nonblack
 GM all (nM) 50 385 (288, 514) 203 409 5 7,039
 GM C12 (nM) 28 385 (257, 578) 186 336 62 15,291
Cmin (nM) 50 80 (56, 114) 221 86 5 1,154
Female vs. male comparison GMR (90% CI)
 GM all female/GM all male 0.89 (0.69, 1.13)
 GM C12h female/GM C12h male 1.17 (0.84, 1.64)
 Cmin female/Cmin male 1.20 (0.89, 1.61)
Black vs. nonblack comparison GMR (90% CI)
 GM all black/GM all nonblack 0.92 (0.69, 1.22)
 GM C12h black/GM C12h nonblack 0.74 (0.50, 1.09)
Cmin black/Cmin nonblack 1.17 (0.83, 1.64)
a

Back-transformed from log scale. LS mean, geometric least-squares mean.

b

%CV=100×sqrt[exp(s2)−1], where s2 is the observed variance on the natural log-scale.

Note: Raltegravir was administered with background antiretroviral therapy.

min, minimum; max, maximum; CI, confidence interval; CV, coefficient of variation; PK, pharmacokinetic; GM, geometric mean.